Related references
Note: Only part of the references are listed.
Article
Mathematical & Computational Biology
The Strong Null Hypothesis and the MaxCombo Test: Comment on Robust Design and Analysis of Clinical Trials with Nonproportional Hazards: A Straw Man Guidance form a Cross-Pharma Working Group.
Dominic Magirr et al.
STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2023)
Review
Oncology
Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials A Systematic Review and Meta-analysis
Pralay Mukhopadhyay et al.
Summary: This study compares the log-rank test with the MaxCombo and dRMST in immuno-oncology trials and evaluates their performance. The findings suggest that MaxCombo may be a pragmatic alternative to log-rank in cases where nonproportional hazards are expected. The results of the different tests show varying sensitivity in detecting treatment differences.
JAMA ONCOLOGY (2022)
Share Paper
